适用于沙库巴曲缬沙坦治疗的心力衰竭患者的健康相关生活质量。
Health-related quality of life in patients with heart failure eligible for treatment with sacubitril-valsartan.
机构信息
Department of Nursing Umeå University Umeå Sweden.
Department of Public Health and Clinical Medicine Umeå University Umeå Sweden.
出版信息
Nurs Open. 2019 Nov 19;7(2):556-562. doi: 10.1002/nop2.420. eCollection 2020 Mar.
AIM
To describe and compare self-reported health-related quality of life between younger and older patients with severe heart failure eligible for treatment with sacubitril-valsartan and to explore the association between health-related quality of life and age, NYHA classification, systolic blood pressure and NT-proBNP level.
DESIGN
Cross-sectional study.
METHODS
A total of 59 patients, eligible for treatment with sacubitril-valsartan were consecutively included and divided into a younger (≤75 years) and older group (>75 years). Health-related quality of life was assessed using the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5-dimensions. Data were collected between June 2016 and January 2018. The STROBE checklist was used.
RESULTS
There were no differences in overall health-related quality of life between the age groups. The older patients reported lower scores in two domains measured with the Kansas City Cardiomyopathy Questionnaire, namely self-efficacy (67.0 22.1 vs. 78.8 19.7) and physical limitation (75.6 19.0 vs. 86.3 14.4). Higher NYHA class was independently associated with lower Kansas City Cardiomyopathy Questionnaire Overall Summary Score.
目的
描述和比较适合使用沙库巴曲缬沙坦治疗的年轻和老年重症心力衰竭患者的自我报告健康相关生活质量，并探讨健康相关生活质量与年龄、纽约心脏协会（NYHA）心功能分级、收缩压和 N 末端 B 型利钠肽前体（NT-proBNP）水平之间的关系。
设计
横断面研究。
方法
连续纳入 59 例适合使用沙库巴曲缬沙坦治疗的患者，并分为年轻（≤75 岁）组和老年（>75 岁）组。采用堪萨斯城心肌病问卷和欧洲五维健康量表评估健康相关生活质量。数据采集时间为 2016 年 6 月至 2018 年 1 月。采用 STROBE 清单。
结果
两组间总体健康相关生活质量无差异。老年组在两个用堪萨斯城心肌病问卷测量的领域报告的评分较低，即自我效能（67.0±22.1 比 78.8±19.7）和身体限制（75.6±19.0 比 86.3±14.4）。较高的 NYHA 心功能分级与堪萨斯城心肌病问卷总体综合评分较低独立相关。
Zotero 插件